173 related articles for article (PubMed ID: 28827680)
1. Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo.
Shirmanova MV; Druzhkova IN; Lukina MM; Dudenkova VV; Ignatova NI; Snopova LB; Shcheslavskiy VI; Belousov VV; Zagaynova EV
Sci Rep; 2017 Aug; 7(1):8911. PubMed ID: 28827680
[TBL] [Abstract][Full Text] [Related]
2. Intracellular pH imaging in cancer cells in vitro and tumors in vivo using the new genetically encoded sensor SypHer2.
Shirmanova MV; Druzhkova IN; Lukina MM; Matlashov ME; Belousov VV; Snopova LB; Prodanetz NN; Dudenkova VV; Lukyanov SA; Zagaynova EV
Biochim Biophys Acta; 2015 Sep; 1850(9):1905-11. PubMed ID: 25964069
[TBL] [Abstract][Full Text] [Related]
3. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells.
Xie J; Wang BS; Yu DH; Lu Q; Ma J; Qi H; Fang C; Chen HZ
Int J Oncol; 2011 Feb; 38(2):409-17. PubMed ID: 21132264
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment.
Shah AT; Diggins KE; Walsh AJ; Irish JM; Skala MC
Neoplasia; 2015 Dec; 17(12):862-870. PubMed ID: 26696368
[TBL] [Abstract][Full Text] [Related]
5. Imaging of Intracellular pH in Tumor Spheroids Using Genetically Encoded Sensor SypHer2.
Zagaynova EV; Druzhkova IN; Mishina NM; Ignatova NI; Dudenkova VV; Shirmanova MV
Adv Exp Med Biol; 2017; 1035():105-119. PubMed ID: 29080133
[TBL] [Abstract][Full Text] [Related]
6. The metabolic interaction of cancer cells and fibroblasts - coupling between NAD(P)H and FAD, intracellular pH and hydrogen peroxide.
Druzhkova IN; Shirmanova MV; Lukina MM; Dudenkova VV; Mishina NM; Zagaynova EV
Cell Cycle; 2016 May; 15(9):1257-66. PubMed ID: 26986068
[TBL] [Abstract][Full Text] [Related]
7. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells.
Laurencot CM; Kennedy KA
Oncol Res; 1995; 7(7-8):371-9. PubMed ID: 8747600
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
9. Relationship between intracellular pH, metabolic co-factors and caspase-3 activation in cancer cells during apoptosis.
Sergeeva TF; Shirmanova MV; Zlobovskaya OA; Gavrina AI; Dudenkova VV; Lukina MM; Lukyanov KA; Zagaynova EV
Biochim Biophys Acta Mol Cell Res; 2017 Mar; 1864(3):604-611. PubMed ID: 28063999
[TBL] [Abstract][Full Text] [Related]
10. Tracing of intracellular pH in cancer cells in response to Taxol treatment.
Druzhkova I; Lukina M; Dudenkova V; Ignatova N; Snopova L; Gavrina A; Shimolina L; Belousov V; Zagaynova E; Shirmanova M
Cell Cycle; 2021 Aug; 20(16):1540-1551. PubMed ID: 34308742
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
Chau Q; Stewart DJ
Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
13. The change of intracellular pH is involved in the cisplatin-resistance of human lung adenocarcinoma A549/DDP cells.
Huang Z; Huang Y
Cancer Invest; 2005; 23(1):26-32. PubMed ID: 15779865
[TBL] [Abstract][Full Text] [Related]
14. Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.
Nath K; Nelson DS; Heitjan DF; Zhou R; Leeper DB; Glickson JD
NMR Biomed; 2015 Mar; 28(3):395-403. PubMed ID: 25702942
[TBL] [Abstract][Full Text] [Related]
15. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin.
Xie SM; Fang WY; Liu Z; Wang SX; Li X; Liu TF; Xie WB; Yao KT
J Transl Med; 2008 Oct; 6():55. PubMed ID: 18834541
[TBL] [Abstract][Full Text] [Related]
16. Metabolic markers of MG-63 osteosarcoma cell line response to doxorubicin and methotrexate treatment: comparison to cisplatin.
Lamego I; Duarte IF; Marques MP; Gil AM
J Proteome Res; 2014 Dec; 13(12):6033-45. PubMed ID: 25382592
[TBL] [Abstract][Full Text] [Related]
17. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
18. PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.
Lai ZY; Yeo HY; Chen YT; Chang KM; Chen TC; Chuang YJ; Chang SJ
Oncotarget; 2017 Jul; 8(28):45323-45334. PubMed ID: 28484083
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol inhibits ovarian tumor growth in an in vivo mouse model.
Tan L; Wang W; He G; Kuick RD; Gossner G; Kueck AS; Wahl H; Opipari AW; Liu JR
Cancer; 2016 Mar; 122(5):722-9. PubMed ID: 26619367
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
Zastre J; Anantha M; Ramsay E; Bally M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):91-102. PubMed ID: 17009029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
